You are here: Industry Insights > AMD

News List

Macular Degeneration Can Rob You of Sight: Know the Signs drugs.com
February 06, 2022
Early diagnosis and care can often stop the progression of age-related macular degeneration (AMD), which is the leading cause...
NIH scientists identify two drug candidates for AMD treatment Pharmaceutical-Technology
December 17, 2021
Researchers at the US National Institutes of Health (NIH) unit National Eye Institute (NEI) have identified two potential drug candidates for age-related macular degeneration (AMD) treatment.
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) firstwordpharma
August 06, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment.
R&D Alliance for Eye Disease Cell Therapies contractpharma
May 18, 2021
BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics enter R&D pact to discover and develop cell therapies for eye diseases.
Roche’s faricimab hits primary endpoint in wet AMD studies pharmatimes
January 27, 2021
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).
EyePoint Reports Positive Results from GLP Toxicology Study of EYP-1901 americanpharmaceuticalreview
December 24, 2020
EyePoint Pharmaceuticals announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® ...
NICE recommends Novartis’ wet AMD drug Beovu pharmatimes
December 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
Levodopa may improve vision in patients with macular degeneration Elsevier
September 24, 2020
Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision.
LumiThera, Diopsys Enrolls of First Subject in Dry AMD ELECTROLIGHT Study americanpharmaceuticalreview
September 18, 2020
LumiThera is collaborating with Diopsys to support a prospective, pilot, human clinical trial in U.S. subjects diagnosed with dry Age-related Macular Degeneration.
DE-122 flops in wet AMD trial pharmatimes
March 12, 2020
Tracon Pharmaceuticals and Santen have decided to halt development of DE-122 for wet age-related macular degeneration (AMD), after reviewing recently obtained top-line data from the Phase IIa AVANTE clinical study.

Previous page 1 2 3 Next page